Some Observations on the Reversibility of Methotrexate Toxicity in Normal Proliferating Tissues
Overview
Authors
Affiliations
Thymidine, in the absence of hypoxanthine, failed to protect normal mice from the acute toxicity of methotrexate, though tumor-bearing animals could be protected with thymidine alone, probably as a result of the availability of DNA degradation products released from drug-sensitive tumor cells. Although metrotrexate induced an early purine deficiency in gut cells, this effect was not detected in bone marrow. Later, purine deficiency became apparent in the gut and bone marrow of methotrexate-treated animals.
Transition from laboratory to clinic in cancer treatment. Abstracts of symposium papers.
Br J Cancer. 1981; 43(5):701-35.
PMID: 7248155 PMC: 2010689. DOI: 10.1038/bjc.1981.102.
Braakhuis B, Schoevers E, Heinerman E, Sneeuwloper G, Snow G Br J Cancer. 1983; 48(5):711-6.
PMID: 6196043 PMC: 2011514. DOI: 10.1038/bjc.1983.254.
Clinical use of thymidine as a rescue agent from methotrexate toxicity.
Grem J, King S, Sorensen J, Christian M Invest New Drugs. 1991; 9(3):281-90.
PMID: 1838364 DOI: 10.1007/BF00176985.